SCHEMBL7665133

SCHEMBL7665133

O=C(Nc1ccc(C=Cc2ccc(NC(=O)c3ccc(OC4CCOCC4)c(S(=O)(=O)N4CCOCC4)c3)cc2S(=O)(=O)O)c(S(=O)(=O)O)c1)c1ccc(OC2CCOCC2)c(S(=O)(=O)N2CCOCC2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.54
ALDH1A1 P00352 8/20 0.54
MAPK1 P28482 7/20 0.54
KMT2A Q03164 7/20 0.54
SMN1; SMN2 Q16637 7/20 0.54
MEN1 O00255 6/20 0.54
L3MBTL1 Q9Y468 3/20 0.54
TSHR P16473 3/20 0.54
KDM4E B2RXH2 3/20 0.54
GAA P10253 3/20 0.54
HSD17B10 Q99714 2/20 0.54
MAPT P10636 2/20 0.50
USP2 O75604 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
HTT P42858 2/20 0.49
DNMT1 P26358 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7665004 1.00 LMNA (0.54) LMNAALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL7666465 0.89 KMT2A (0.68) LMNAALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL7666544 0.89 KMT2A (0.68) LMNAALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL8019200 0.87 LMNA (0.55) LMNAALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL7673053 0.85 MAPK1 (0.59) LMNAALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL7669200 0.85 MAPK1 (0.59) LMNAALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL7658982 0.83 LMNA (0.64) LMNAALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL7658968 0.83 LMNA (0.64) LMNAALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL7668133 0.83 ALDH1A1 (0.63) LMNAALDH1A1MAPK1KMT2ASMN1; SMN2
SCHEMBL7666320 0.83 LMNA (0.56) LMNAALDH1A1MAPK1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020111369-A1 Aryl sulfonic acids and derivatives as FSH antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-08-15 US claimed
WO-2000058277-A1 ARYL SULFONIC ACIDS AND DERIVATIVES AS FSH ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-10-05 WO claimed
US-20020111369-A1 Aryl sulfonic acids and derivatives as FSH antagonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-08-15 US disclosed
US-6355633-B1 CONTRACEPTIVES AMERICAN HOME PRODUCTS CORPORATION 2002-03-12 US disclosed
WO-2000058277-A1 ARYL SULFONIC ACIDS AND DERIVATIVES AS FSH ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111369-A1 Aryl sulfonic acids and derivatives as FSH antagonists FSHR, GNRHR, LHCGR LMNA 3330/4885ALDH1A1 3990/4885MAPK1 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.